845829-93-8Relevant academic research and scientific papers
NEW BIARYL AMIDE DERIVATIVES
-
Page/Page column 23-24, (2012/07/13)
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and A are as described herein, compositions including the compounds and methods of using the compounds.
NEW BIARYL AMIDE DERIVATIVES
-
Page/Page column 58, (2012/07/14)
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and A are as described herein, compositions including the compounds and methods of using the compounds.
Novel small molecule bradykinin B1 receptor antagonists. Part 1: Benzamides and semicarbazides
Schaudt, Marco,Locardi, Elsa,Zischinsky, Gunther,Stragies, Roland,Pfeifer, Jochen R.,Gibson, Christoph,Scharn, Dirk,Richter, Uwe,Kalkhof, Holger,Dinkel, Klaus,Schnatbaum, Karsten
scheme or table, p. 1225 - 1228 (2010/06/15)
The synthesis and SAR of two series of bradykinin B1 receptor antagonists is described. The benzamide moiety proved to be a suitable replacement for the aryl ester functionality of biaryl based antagonists. In addition, it was found that semica
Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists
Kuduk, Scott D.,Di Marco, Christina N.,Chang, Ronald K.,Wood, Michael R.,Schirripa, Kathy M.,Kim, June J.,Wai, Jenny M. C.,DiPardo, Robert M.,Murphy, Kathy L.,Ransom, Richard W.,Harrell, C. Meacham,Reiss, Duane R.,Holahan, Marie A.,Cook, Jacquelynn,Hess, J. Fred,Sain, Nova,Urban, Mark O.,Tang, Cuyue,Prueksaritanont, Thomayant,Pettibone, Douglas J.,Bock, Mark G.
, p. 272 - 282 (2007/10/03)
A series of biphenylaminocyclopropane carboxamide based bradykinin B 1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in t
SULFONYL SUBSTITUTED N-(BIARYLMETHYL) AMINOCYCLOPROPANECARBOXAMIDES
-
, (2008/06/13)
N-(Sulfonyloxybiarylmethyl) aminocyclopropanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
